EHP-101

MS Therapy EHP-101 Boosts Blood Vessel Growth, Targets Inflammation

EHP-101, an experimental treatment being clinically tested for multiple sclerosis (MS), activates a cellular signaling pathway that promotes blood vessel development and reduces inflammation following brain injury, a new study shows. The findings continue to support the use of EHP-101 in MS, a condition marked by excess inflammation and…

Phase 1 Clinical Trial of EHP-101 Concludes with Positive Safety Results

The first in-human clinical trial of EHP-101, an investigational treatment for multiple sclerosis (MS) and systemic scleroderma (SSc), has been successfully completed,Ā Emerald Health PharmaceuticalsĀ (EHP) announced. EHP-101 demonstrated it was safe and well-tolerated in healthy volunteers, supporting further clinical development ofĀ EHP-101 in future Phase 2 clinical trials. The…

Cannabidiol-derived Treatment for MS, EHP-101, Enters Phase 1 Safety Study, Emerald Health Says

Emerald Health PharmaceuticalsĀ announced that it has begun enrolling healthy volunteers for a Phase 1 clinical trial evaluating the safety and tolerability ofĀ EHP-101,Ā a potential cannabidiol treatment for multiple sclerosis (MS) and scleroderma. The randomized, double-blind, and placebo-controlled study (ACTRN12618001390279p) will Ā investigate the safety and pharmacokinetics (how…

Work Showing Potential of EHP-101 in MS Earns Research Award

Carmen Navarrete, PhD, has been granted a Scientific Innovation Award for her post-doctoral presentation suggesting that theĀ multiple sclerosisĀ (MS) treatment candidateĀ EHP-101Ā is anti-inflammatory and may boost remyelination,Ā Emerald Health PharmaceuticalsĀ announced. Navarrete, a senior scientist at Vivacell Biotechnology Espana, a company owned by Emerald Health Research, received the award at the…